Are pharmaceutical supply chains responsible for the opioid epidemic?

| January 3, 2017

article image
Cardinal Health, which supplies drugs to 25,000 pharmacies and 70,000 hospitals nationwide, agreed to pay the Department of Justice $44 million to settle civil penalties from a 2012 Drug Enforcement Agency (DEA) case against the company for its negligence in stemming the national opioid epidemic. Pharmaceutical suppliers are responsible for notifying the DEA of suspciously large or frequent orders, as part of required anti-diversion programs along the supply chain, The Baltimore Sun reports. The case began when an excessive amount of oxycodone in Florida, Maryland and New York was found to have originated at Cardinal's Lakeland, FL distribution site, with no reports of suspicious orders filed. A temporary suspension, legal battle and several settlements follower.

Spotlight

Reach Separations

Reach Separations specialises in chromatography for the analysis and purification of small molecules. We provide a high quality and efficient service to our clients returning samples and results quickly, allowing them to streamline their internal processes and accelerate their discovery programmes. The latest HPLC and SFC technologies are used side by side to effectively support our clients across the pharmaceutical, agrochemical and fine chemical sectors. As experts in chiral separation we have become an economical solution for a large and varied client base throughout the UK and Europe.

OTHER ARTICLES

Decentralized Clinical Trials: Imperative for Pharma Sector to fight COVID19

Article | April 3, 2020

These are unprecedented times. The world is mobbed by a contagion virus, putting people’s health at risk, threatening to destabilize economies. It has already put global healthcare systems under tremendous pressures, and managed to resist efforts to contain it. Even though coronaviruses are not new, this COVID-19 strain has created panic and forced us to be locked down in our homes sans any movement for weeks, if not months. Organizations are fighting an intense battle to keep their workforce safe, minimize risk, and ensure business continuity. For the Life Sciences industry, however, the challenge is even more significant. The whole world is looking at them to come up with a vaccine and a cure. But that is easier said than done. Bringing a new drug to market is an uphill battle and requires rigorous clinical trials. This process already has regulatory challenges. With the current lockdown situation, the Pharma community is grappled with the challenge of continuing some of the critical and time-sensitive in-flight trials so that their regulatory submission, registration, and market entry are not impacted. But all may not be lost. With the right technology solution, it is possible to turn the situation around rapidly.

Read More

Five Ways to Manage Your Trial Effectively in a Fast-Changing Global Environment

Article | March 11, 2020

Over the past half-century, clinical trials have grown increasingly complex. A flood of new data from novel sources combined with more elaborate study designs and tougher regulatory standards have lengthened timelines and hiked costs, contributing to a steady decline of efficiency. It all adds up: Nearly half of all drug launches underperform revenue expectations. And if that isn’t enough, the outbreak of COVID-19 worldwide is having an effect on how life sciences companies operate their businesses, including how clinical trials are conducted. Most clinical trial research organizations have tried to adapt by tweaking a platform here, adding a new app there, but this has only yielded patchwork systems of sites, spreadsheets and dashboards that further burden the process.

Read More

How Pharma Companies Can Scale Up Their Knowledge Discovery with Semantic Similarity Search

Article | March 6, 2020

Pharma has deep roots in human history with centuries of folk pharmaceutical knowledge offering a hit-and-miss range of natural remedies. But the industry as we know it today actually emerged in the second half of the 19th century when the world’s first factory for the sole production of medicines was found. By the late 19th and early 20th century, some chemical companies had already begun using research labs to explore the medical applications for their products. Fast forward to today and the pharmaceutical sector is a global trillion-dollar industry. However, to ensure the safety and efficacy of drugs, the process of drug discovery and development is under extensive scrutiny and control on both national and global levels.

Read More

As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

Article | April 17, 2020

That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute.

Read More

Spotlight

Reach Separations

Reach Separations specialises in chromatography for the analysis and purification of small molecules. We provide a high quality and efficient service to our clients returning samples and results quickly, allowing them to streamline their internal processes and accelerate their discovery programmes. The latest HPLC and SFC technologies are used side by side to effectively support our clients across the pharmaceutical, agrochemical and fine chemical sectors. As experts in chiral separation we have become an economical solution for a large and varied client base throughout the UK and Europe.

Events